Gilead Sciences Read More
Search
Gilead Sciences
Gilead Sciences Announces Partnership with PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- & Lower-Middle-Income Countries
Gilead Sciences Read More
Gilead Statement on New CDC Guidelines on Twice-Yearly Yeztugo® (Lenacapavir) for HIV Prevention
Gilead Sciences Read More
NIH Ponders Overhauling HIV Budget to Capitalize on Prevention Breakthrough
Gilead Sciences Read More
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV
Gilead Sciences Read More
EU Approves New Injection for Preventing HIV
Gilead Sciences Read More
Gilead Sciences and Global Fund Finalize Plan to Supply HIV Prevention Drug to Poor Countries
Gilead Sciences Read More
The Decades-Long Journey to the Twice-a-Year HIV Prevention Drug Lenacapavir
Gilead Sciences Read More
Gilead Says Its Therapy Delayed Growth of Tumors in Aggressive Form of Breast Cancer
Gilead Sciences Read More
Gilead Sciences Data suggest Once-Yearly Shot of PrEP Drug Blocks HIV Infection
Gilead Sciences Read More
Using Lessons from the HIV Epidemic to Help Reduce Stigma Around Lung Cancer
Gilead Read More
Global Fund, PEPFAR Announce Coordinated Effort to Reach 2 Million People with Lenacapavir for PrEP to Significantly Reduce Global HIV Infections
Gilead Sciences Read More
Gilead’s Twice-Yearly Antiviral Protects Against HIV Infection in Second Large Trial
Gilead Read More
Gilead Sciences: Living With a Rare Liver Disease: Maria’s Journey
Gilead Sciences Read More
Turning the tide on HIV in Eastern Europe and Central Asia: The RADIAN initiative by Gilead and the Elton John AIDS Foundation | Devex Summit | UNGA79
Join Devex in partnership with Alliance member Gilead Sciences for ‘Turning the tide on HIV in Eastern Europe and Central Asia: The RADIAN initiative by Gilead and the Elton John AIDS Foundation’ featuring speaker Carmen Villar, Vice president, ESG and corporate citizenship, Gilead Sciences on September 25, 2024 at 12:10 PM ET.
Berkeley Public Health partners with Gilead for new research and executive education initiative
UC Berkeley, Gilead Sciences Read More
Building Bridges, Uniting for Impact: 2024 Annual Meeting
“Global health really is a team effort,” said Colin Boyle, Alliance board chair and Lecturer at UC Berkeley Haas School of Business, opening the Bay Area Global Health Alliance’s 4th Annual Meeting, where multisectoral members convened on May 21 to discuss bridging gaps and enhancing collaborative efforts across various sectors to tackle pressing health issues worldwide.
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Gilead Sciences Read More
San Francisco AIDS Walk
Join Alliance members Chevron and Gilead Sciences for AIDS Walk San Francisco 2024. This event brings people from across the region together to remember those we’ve lost, show solidarity and support for those still fighting, and look to a future where HIV/AIDS is finally eradicated.
Building Bridges, Uniting for Impact: 2024 Annual Meeting
The Bay Area Global Health Alliance’s Annual Meeting will bring together members to discuss pressing global health issues, including: innovations and investments for women’s health equity, overcoming barriers in multi-sector global health partnerships, and putting health at the heart of global climate change action. Speakers include leaders from Wellcome Trust, Accenture Development Partnerships, Africa Health Business, Americares, Cross-Border Impact Ventures, Gilead Sciences, Google, Merck for Mothers, PATH, Roche Diagnostics, and more.